Hualan Biological Engineering Inc
SZSE:002007

Watchlist Manager
Hualan Biological Engineering Inc Logo
Hualan Biological Engineering Inc
SZSE:002007
Watchlist
Price: 16.68 CNY -4.08% Market Closed
Market Cap: 30.4B CNY
Have any thoughts about
Hualan Biological Engineering Inc?
Write Note

Hualan Biological Engineering Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hualan Biological Engineering Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Hualan Biological Engineering Inc
SZSE:002007
Cash from Operating Activities
ÂĄ1.1B
CAGR 3-Years
-12%
CAGR 5-Years
-4%
CAGR 10-Years
7%
Beigene Ltd
HKEX:6160
Cash from Operating Activities
-ÂĄ7.8B
CAGR 3-Years
-15%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Operating Activities
ÂĄ1.5B
CAGR 3-Years
49%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cash from Operating Activities
ÂĄ796.9m
CAGR 3-Years
-13%
CAGR 5-Years
9%
CAGR 10-Years
13%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Operating Activities
ÂĄ6.5B
CAGR 3-Years
-12%
CAGR 5-Years
54%
CAGR 10-Years
43%
Imeik Technology Development Co Ltd
SZSE:300896
Cash from Operating Activities
ÂĄ2B
CAGR 3-Years
66%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

Hualan Biological Engineering Inc
Glance View

Market Cap
30.5B CNY
Industry
Biotechnology

Hualan Biological Engineering, Inc. engages in the research and development, production, and sale of biological products. The company is headquartered in Xinxiang, Henan and currently employs 2,927 full-time employees. The company went IPO on 2004-06-25. The company also produces vaccine products and biological engineering products. The firm's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus immunoglobulin and influenza vaccines, among others. The firm mainly operates its businesses in domestic markets.

Intrinsic Value
26.98 CNY
Undervaluation 38%
Intrinsic Value
Price

See Also

What is Hualan Biological Engineering Inc's Cash from Operating Activities?
Cash from Operating Activities
1.1B CNY

Based on the financial report for Sep 30, 2024, Hualan Biological Engineering Inc's Cash from Operating Activities amounts to 1.1B CNY.

What is Hualan Biological Engineering Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
7%

Over the last year, the Cash from Operating Activities growth was -28%. The average annual Cash from Operating Activities growth rates for Hualan Biological Engineering Inc have been -12% over the past three years , -4% over the past five years , and 7% over the past ten years .

Back to Top